Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Acute pancreatitis · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
1 finding from 1 review
Intervention not reported
Bone marrow suppression · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
1 finding from 1 review
Any adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
1 finding from 1 review
Intervention not reported
Any adverse event · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes any adverse event (very low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal due to adverse event · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes withdrawal due to adverse event (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
Mucosal healing · Patients with active Crohn's disease
Azathioprine + infliximab probably leads to higher mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review